Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
Completed · Phase 1 · NCT03905148
Conditions: Solid Tumor, Adult
At a glance
- Research payments reported, 2025
- $373,605
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 91
About the trial
- Sponsor
- BeiGene (with Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany)
- Tested
- Lifirafenib (drug), mirdametinib (drug)
- Dates
- Started 2019-05-01; completion 2025-10-23
- Results posted
- Not yet
This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.
From ClinicalTrials.gov, last updated 2026-01-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene Aus Pty Ltd reported $373,605 in research payments for this study in 2025 (12 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lee S. Rosen, M.D. Specialist · Santa Monica, CA
- Jordan Ahnert, APRN Cardiology · Brunswick, GA
- Sanjay Goel, MD Medical Oncology · New Brunswick, NJ
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $294,370
- Ronald Reagan UCLA Medical Center, CA $57,550
- Rutgers, the State University $21,685
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.